Get started
Author

Angelo Martignetti

Observed names: A MARTIGNETTI, A Martignetti, A. Martignetti, Angelo MARTIGNETTI
OpenAlex ID: A5000699628
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
2001 · G Vitale, F Fonderico, et al. · British Journal of Cancer · 118
PDF
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
2018 · L. Malorni, G. Curigliano, et al. · Annals of Oncology · 109
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
2015 · S. Bracarda, R. Iacovelli, et al. · Annals of Oncology · 104
PDF
Somatostatin analogs and prednisone in advanced refractory thymic tumors
2002 · Giovannella Palmieri, Liliana Montella, et al. · Cancer · 103
Identification of tumor‐associated antigens by screening phage‐displayed human cDNA libraries with sera from tumor patients
2003 · Olga Minenkova, Andrea Pucci, et al. · International Journal of Cancer · 88
PDF
Art therapy with cancer patients during chemotherapy sessions: An analysis of the patients' perception of helpfulness
2010 · Silvia Forzoni, Michela Perez, et al. · Palliative & Supportive Care · 83
Triple-Negative Breast Cancer: Current State of the Art
2010 · Francesca Rastelli, Sandra Biancanelli, et al. · Tumori Journal · 72
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial
2019 · Gianluca Masi, Caterina Vivaldi, et al. · European Journal of Cancer · 44
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
2017 · Federica Marmorino, Lisa Salvatore, et al. · British Journal of Cancer · 40
PDF
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
2022 · Matteo Santoni, Francesco Massari, et al. · European Urology Focus · 38
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer
2007 · Maria Giulia Zampino, Elena Magni, et al. · Cancer · 37
PDF
Cancer patients as `experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO)
2000 · M. Costantini, E. Mencaglia, et al. · Quality of Life Research · 36
Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report.
2000 · G Palmieri, L Montella, et al. · Oncology Reports · 33
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
2019 · Lorenzo Rossi, Chiara Biagioni, et al. · Breast Cancer Research · 31
PDF
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
2019 · Matteo Santoni, Daniel Y. Heng, et al. · Cancers · 30
PDF
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
2023 · Ondřej Fiala, Sebastiano Buti, et al. · Cancer Immunology Immunotherapy · 29
PDF
Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma
2002 · Giovannella Palmieri, Liliana Montella, et al. · American Journal of Clinical Oncology · 29
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
2018 · Beatrice Borelli, Roberto Moretto, et al. · ESMO Open · 25
PDF
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025 · P. Ciracì, M.M. Germani, et al. · Annals of Oncology · 24
PDF
Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration
1998 · Pierosandro Tagliaferri, Carmen Barile, et al. · American Journal of Clinical Oncology · 24
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma
2022 · Matteo Santoni, Francesco Massari, et al. · European Journal of Cancer · 23
Tivozanib for the treatment of renal cell carcinoma
2018 · Matteo Santoni, Francesco Massari, et al. · Expert Opinion on Pharmacotherapy · 22
Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
2002 · Claudia Pizzi, Michele Caraglia, et al. · PubMed · 22
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
2021 · Roberto Moretto, Daniele Rossini, et al. · Clinical Colorectal Cancer · 21
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers
2019 · Matteo Santoni, Alessia Cimadamore, et al. · Cancers · 19
PDF
Works count: 52
Citation count: 1,329
H-index: 22
I10-index: 31
Year
Topic
Type